Literature DB >> 1201465

Reversible extinction of the morphogen in bone matrix by reduction and oxidation of disulfide bonds.

M R Urist, A Mikulski, C N Conteas.   

Abstract

Beta-Mercaptoethanol (beta-ME) or dithiothreitol (DTT) reduction extinguishes the capacity of bone matrix gelatin to produce new bone following implantation in a muscle pouch. If the reducing solution is used in concentrations of 50 mmoles/l or less, the extinction can be partially reversed by bubbling of oxygen through the solution for one hour. Sulfhydryl group blocking reagents prevent reoxidation of reduced bone gelatin, and restoration of the bone morphogenetic property (BMP). Unspecific borohydride reduction at 37 degrees destroys bone yield irreversibly, but at 2 degrees reduction of free aldehyde groups in bone gelatin does not prevent beta-ME and DTT reversible extinction. These observations are interpreted to suggest that the disulphide linkage may be an essential part of the biologically active conformation of either a non-collagenous bone morphogenetic polypeptide firmly bound to collagen or a collagen by-product entrapped within a water insoluble gel matrix.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1201465     DOI: 10.1007/bf02563992

Source DB:  PubMed          Journal:  Calcif Tissue Res        ISSN: 0008-0594


  7 in total

1.  Bone morphogenesis in implants of residues of radioisotope labelled bone matrix.

Authors:  M R Urist; F Earnest; K M Kimball; T P Di Julio; H Iwata
Journal:  Calcif Tissue Res       Date:  1974

2.  Preservation and biodegradation of the morphogenetic property of bone matrix.

Authors:  M R Urist; H Iwata
Journal:  J Theor Biol       Date:  1973-01       Impact factor: 2.691

3.  Origin of the indutive signal in implants of normal and lathyritic bone matrix.

Authors:  B S Strates; M R Urist
Journal:  Clin Orthop Relat Res       Date:  1969 Sep-Oct       Impact factor: 4.176

4.  Observations implicating an extracellular enzymic mechanism of control of bone morphogenesis.

Authors:  M R Urist; H Iwata; S D Boyd; P L Ceccotti
Journal:  J Histochem Cytochem       Date:  1974-02       Impact factor: 2.479

5.  Bone morphogenetic protein.

Authors:  M R Urist; B S Strates
Journal:  J Dent Res       Date:  1971 Nov-Dec       Impact factor: 6.116

6.  Bone morphogenesis in implants of insoluble bone gelatin.

Authors:  M R Urist; H Iwata; P L Ceccotti; R L Dorfman; S D Boyd; R M McDowell; C Chien
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

7.  Biochemistry of collagen crosslinking. Isolation of a new crosslink, hydroxylysinohydroxynorleucine, and its reduced precursor, dihydroxynorleucine, from bovine tendon.

Authors:  G Mechanic; M L Tanzer
Journal:  Biochem Biophys Res Commun       Date:  1970-12-24       Impact factor: 3.575

  7 in total
  6 in total

1.  Solubilized and insolubilized bone morphogenetic protein.

Authors:  M R Urist; A Mikulski; A Lietze
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

2.  [Osteoblasts : cellular and molecular regulatory mechanisms in fracture healing].

Authors:  A Hofmann; S G Mattyasovszky; C Brüning; U Ritz; I Mehling; A Meurer; P M Rommens
Journal:  Orthopade       Date:  2009-11       Impact factor: 1.087

Review 3.  [Osteoinduction and -reparation].

Authors:  N R Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  1997-02

4.  Bone-derived factors active on bone cells.

Authors:  S Mohan; T Linkhart; J Farley; D Baylink
Journal:  Calcif Tissue Int       Date:  1984       Impact factor: 4.333

5.  Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography.

Authors:  M R Urist; Y K Huo; A G Brownell; W M Hohl; J Buyske; A Lietze; P Tempst; M Hunkapiller; R J DeLange
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

Review 6.  Bone morphogenetic protein: a review.

Authors:  G Aldinger; G Herr; W Küsswetter; H J Reis; F W Thielemann; U Holz
Journal:  Int Orthop       Date:  1991       Impact factor: 3.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.